Results 231 to 240 of about 3,814,825 (281)
Some of the next articles are maybe not open access.
Antiplatelet Agents for Stroke Prevention
Cerebrovascular Diseases, 2000Antiplatelet agents for stroke ...
Paciaroni M, Gallai V
openaire +3 more sources
Antiplatelets agents and anticoagulants for hypertension
2001Although elevated systemic blood pressure results in high intravascular pressure, the main complications, coronary heart disease (CHD), ischaemic strokes and peripheral vascular disease (PVD), are related to thrombosis rather than haemorrhage. Some complications related to elevated blood pressure, heart failure or atrial fibrillation, are themselves ...
G Y H, Lip, D C, Felmeden
openaire +2 more sources
2018
Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention. Several landmark studies for the optimal duration and dose of antiplatelet therapy in stroke prevention are discussed.
Eelco F. M. Wijdicks, Sarah L. Clark
openaire +2 more sources
Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention. Several landmark studies for the optimal duration and dose of antiplatelet therapy in stroke prevention are discussed.
Eelco F. M. Wijdicks, Sarah L. Clark
openaire +2 more sources
Food and Chemical Toxicology, 2018
Platelets are involved in hemostasis, inflammation, and thrombosis processes. Following a vascular damage, the endothelium releases protein factors, allowing the adhesion of subendothelium to platelets.
Harron Khan +6 more
semanticscholar +1 more source
Platelets are involved in hemostasis, inflammation, and thrombosis processes. Following a vascular damage, the endothelium releases protein factors, allowing the adhesion of subendothelium to platelets.
Harron Khan +6 more
semanticscholar +1 more source
High Blood Pressure & Cardiovascular Prevention, 2023
Javad Sharifi‐Rad +14 more
semanticscholar +1 more source
Javad Sharifi‐Rad +14 more
semanticscholar +1 more source
Antiplatelet agents for intermittent claudication
Cochrane Database of Systematic Reviews, 2011Peripheral arterial disease (PAD) is common and is a marker of systemic atherosclerosis. Patients with symptoms of intermittent claudication (IC) are at increased risk of cardiovascular events (myocardial infarction (MI) and stroke) and of both cardiovascular and all cause mortality.To determine the effectiveness of antiplatelet agents in reducing ...
Peng F, Wong +4 more
openaire +2 more sources
Clopidogrel: a novel antiplatelet agent
Hospital Medicine, 1999Clopidogrel is a novel antiplatelet agent that has a different mechanism of action to aspirin. Clopidogrel is chemically related to ticlopidine, both of which are more effective than aspirin in preventing some thrombotic events, but it has a safer sideeffect profile than ticlopidine. It is likely to add to the antithrombotic armoury and reduce vascular
S, D'Sa, S J, Machin
openaire +2 more sources
A new generation of antiplatelet agents
Current Opinion in Cardiology, 2009Since the development and market entry of clopidogrel, a platelet ADP blocker, physicians have had few new antiplatelet options available to them for the treatment of acute and chronic coronary disease, specifically in the setting of acute coronary syndromes, percutaneous coronary intervention, and chronic stent management.
Matthew B, Sellers +2 more
openaire +2 more sources
Platelet physiology and antiplatelet agents
Clinical Chemistry and Laboratory Medicine, 2010Apart from the central beneficial role platelets play in hemostasis, they are also involved in atherothrombotic diseases. Here, we review the current knowledge of platelet intracellular signal transduction pathways involved in platelet adhesion, activation, amplification of the activation signal and aggregation, as well as pathways limiting platelet ...
Tim, Thijs +3 more
openaire +2 more sources
Thrombin antagonists and antiplatelet agents
The American Journal of Cardiology, 1992The clinical benefits of thrombolytic therapy for the treatment of myocardial infarction are recognized widely. However, 2 major limiting factors have become evident: (1) 20-25% of coronary arterial thrombi are resistant to lysis; and (2) coronary reocclusion occurs in 10-15% of patients.
openaire +2 more sources